Publish in this journal
Journal Information
Vol. 73. Issue 8.
Pages 691-693 (August 2020)
Share
Share
Download PDF
More article options
Vol. 73. Issue 8.
Pages 691-693 (August 2020)
Letter to the Editor
DOI: 10.1016/j.rec.2020.05.009
Full text access
COVID-19 and treatment guided by biochemical and molecular diagnostic tests to reduce myocardial damage and cardiotoxicity
COVID-19 y tratamiento guiado con tests de diagnóstico bioquímicos y moleculares para reducir el daño cardiaco y la cardiotoxicidad
Visits
...
Sonia Eirasa,b, Ezequiel Álvarezb,c, María Briónb,d, José Ramón González-Juanateyb,c,e,
Corresponding author
a Grupo de Cardiología Traslacional, Instituto de Investigación Sanitaria, Santiago de Compostela, A Coruña, Spain
b Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, CIBERCV, Madrid, Spain
c Grupo de Cardiología, Instituto de Investigación Sanitaria, Santiago de Compostela, A Coruña, Spain
d Grupo de Genética Cardiovascular, Instituto de Investigación Sanitaria, Santiago de Compostela, A Coruña, Spain
e Servicio de Cardiología, Hospital Clínico de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Full Text
To the Editor,

Because of the lack of scientific evidence on the effect of cardiovascular treatment on the infectivity of SARS-CoV-2 and on COVID-19 disease progression, the mechanisms that increase the risk of cardiac damage and thrombosis in patients with COVID-19, and the cardiotoxicity of antiviral treatment, we must consider the need for diagnostic tests that help health care professionals when making therapeutic decisions. Important aspects to consider are the following 5 points:

  • 1.

    Hypertension, diabetes, and cardiovascular disease are the most prevalent comorbidities in patients with COVID-19.1 Although they do not appear to affect the infectivity of the virus,2 they do increase disease severity. One of the common mechanisms of this effect is via the renin-angiotensin-aldosterone system. Their treatment reduces levels and activity of angiotensin II, as it contributes to inflammation and endothelial dysfunction. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) and the protease TMPRSS2 to enter the host cell. ACE2 converts angiotensin II into an isoform with anti-inflammatory and vasodilator activity. It has not yet been ascertained whether the overexpression of tissue ACE2, in pathological states or induced by treatment, increases infection with SARS-CoV-2 or makes up for its deficiency to reduce cardiac, pulmonary, and renal inflammation and vasoconstriction. It is also necessary to study the regulation of serum ACE2 levels and its role in reducing the affinity of SARS-CoV-2 for tissue ACE2 and, consequently, infection (figure 1).

    Figure 1.

    Representation of the importance of angiotensin-converting enzyme 2 (ACE2) and the protease TMPRSS2 for the initial infection with SARS-CoV-2. Polymorphisms of ACE2 or soluble ACE2 may affect its cell binding. The increase in tissue expression of ACE2 may increase the infectivity or have a protective effect, converting angiotensin II to angiotensin (1-7). Ang, angiotensin.

    (0.32MB).
  • 2.

    Determination of the genetic variants of ACE2 in the population could identify which group has least risk of infection with SARS-CoV-2. Of particular interest would be those described as being associated with essential hypertension (rs2074192) and atrial fibrillation (rs4240157, rs4646155, rs4830542).3 The variants SLCO1B1 and BDKRB2,4 associated with patients with toxicity from angiotensin-converting enzyme inhibitors and with symptoms similar to COVID-19, could also be used to exclude false positives.

  • 3.

    A high percentage of patients with COVID-19 have cardiac events while in hospital. Therefore, there is a strong need for plasma markers of cardiac damage such as high-sensitivity cardiac troponin I or lactate dehydrogenase and markers of cardiac function.

  • 4.

    There is also a high prevalence of macrovascular and microvascular thrombotic events in patients with COVID-19. High concentrations of D-dimer, a protein degradation product of coagulation, have been shown to be predictors of mortality.5 However, determination of markers in the initial phase of coagulation could alert to cardiovascular, cerebrovascular, pulmonary, and renal events. We must not forget that ACE2 is expressed in the endothelium and its activation by proinflammatory cytokines triggers the production of tissue factor, platelet adhesion, and activation of the clotting cascade (figure 2).

    Figure 2.

    Representation of the coagulation process. Coagulation factors and D-dimer as markers in COVID-19. TF, tissue factor.

    (0.12MB).
  • 5.

    The treatments used in patients with COVID-19 are based on reducing viral reproduction and inflammation (such as 4-aminoquinolone antimalarial agents). However, these drugs could cause cardiotoxicity, with systolic dysfunction and prolongation of the QT interval.6 Therefore, early markers are required to prevent irreversible cardiotoxicity.

In conclusion, the preventative and therapeutic strategies for COVID-19 will improve with markers that identify those patients with greater pathological, genetic or pharmacological susceptibility to infection with SARS-CoV-2 (ACE2 regulation) and that monitor the mechanisms involved in disease progression (cardiac damage, thrombosis, and cardiotoxicity).

.

References
[1]
J. Yang, Y. Zheng, X. Gou, et al.
Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis.
[2]
B. Li, J. Yang, F. Zhao, et al.
Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.
[3]
Y. Luo, C. Liu, T. Guan, et al.
Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang.
Hypertens Res., 42 (2019), pp. 681-689
[4]
S. Mukae, S. Itoh, S. Aoki, et al.
Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough.
J Hum Hypertens., 16 (2002), pp. 857-863
[5]
F. Zhou, T. Yu, R. Du, et al.
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
[6]
E. Joyce, A. Fabre, N. Mahon.
Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review.
Eur Heart J Acute Cardiovasc Care., 2 (2013), pp. 77-83
Copyright © 2020. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?